9 Meters Biopharma NMTR Stock
9 Meters Biopharma Price Chart
9 Meters Biopharma NMTR Financial and Trading Overview
| 9 Meters Biopharma stock price | 0.15 USD |
| Previous Close | 0.72 USD |
| Open | 0.73 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 1000 |
| Day's Range | 0.7 - 0.74 USD |
| 52 Week Range | 0.58 - 11.4 USD |
| Volume | 48.12K USD |
| Avg. Volume | 77.63K USD |
| Market Cap | 10.2M USD |
| Beta (5Y Monthly) | 1.358098 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.38 USD |
NMTR Valuation Measures
| Enterprise Value | 8.43M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.27869564 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.194 |
Trading Information
9 Meters Biopharma Stock Price History
| Beta (5Y Monthly) | 1.358098 |
| 52-Week Change | -93.14% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.4 USD |
| 52 Week Low | 0.58 USD |
| 50-Day Moving Average | 0.91 USD |
| 200-Day Moving Average | 2.1 USD |
NMTR Share Statistics
| Avg. Volume (3 month) | 77.63K USD |
| Avg. Daily Volume (10-Days) | 44.43K USD |
| Shares Outstanding | 14.46M |
| Float | 12.76M |
| Short Ratio | 4.69 |
| % Held by Insiders | 1.66% |
| % Held by Institutions | 16.43% |
| Shares Short | 589.42K |
| Short % of Float | 4.13% |
| Short % of Shares Outstanding | 4.07% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -111.78% |
| Return on Equity (ttm) | -375.63% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -43432068 USD |
| Net Income Avi to Common (ttm) | -46283132 USD |
| Diluted EPS (ttm) | -3.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.94M USD |
| Total Cash Per Share (mrq) | 0.48 USD |
| Total Debt (mrq) | 5.17M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.59 |
| Book Value Per Share (mrq) | -0.439 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -37244560 USD |
| Levered Free Cash Flow (ttm) | -21021660 USD |
Profile of 9 Meters Biopharma
| Country | United States |
| State | NC |
| City | Raleigh |
| Address | 4509 Creedmoor Road |
| ZIP | 27612 |
| Phone | 919 275 1933 |
| Website | https://www.9meters.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 10 |
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina.
Q&A For 9 Meters Biopharma Stock
What is a current NMTR stock price?
9 Meters Biopharma NMTR stock price today per share is 0.15 USD.
How to purchase 9 Meters Biopharma stock?
You can buy NMTR shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for 9 Meters Biopharma?
The stock symbol or ticker of 9 Meters Biopharma is NMTR.
Which industry does the 9 Meters Biopharma company belong to?
The 9 Meters Biopharma industry is Biotechnology.
How many shares does 9 Meters Biopharma have in circulation?
The max supply of 9 Meters Biopharma shares is 70.17M.
What is 9 Meters Biopharma Price to Earnings Ratio (PE Ratio)?
9 Meters Biopharma PE Ratio is 0.00000000 now.
What was 9 Meters Biopharma earnings per share over the trailing 12 months (TTM)?
9 Meters Biopharma EPS is 0 USD over the trailing 12 months.
Which sector does the 9 Meters Biopharma company belong to?
The 9 Meters Biopharma sector is Healthcare.
9 Meters Biopharma NMTR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}